Global Gastric Volvulus Treatment Market Analysis 2024 – Estimated Market Size And Key Drivers

The Gastric Volvulus Treatment by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Gastric Volvulus Treatment Market:
https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

According to The Business Research Company’s Gastric Volvulus Treatment, The gastric volvulus treatment market size has grown strongly in recent years. It will grow from $25.6 billion in 2023 to $27.18 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%.  The  growth in the historic period can be attributed to advancements in surgical techniques, improved diagnostic technologies, awareness and education, rise in minimally invasive procedures, research and clinical studies.

The gastric volvulus treatment market size is expected to see strong growth in the next few years. It will grow to $34.63 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%.  The growth in the forecast period can be attributed to regulatory changes and approvals, innovations in surgical procedures, growing geriatric population, customized treatment plans, adoption of advanced imaging techniques.. Major trends in the forecast period include minimally invasive surgical techniques, awareness and early intervention, research in treatment modalities, collaborative medical practices, customized treatment approaches.

A rising geriatric population is expected to propel the growth of the gastric volvulus treatment market going forward. The geriatric population refers to older adults 65 years and beyond. The geriatric population suffers from various diseases due to low immunity and age. Gastric volvulus occurs in older adults over the age of 50, hence, the rise in the geriatric population is expected to propel the market. For instance, in November 2022, according to America’s Health Rankings, a US-based partnership between the United Health Foundation and the American Public Health Association, in 2021, more than 55.8 million people aged 65 and above were present in the United States, accounting for nearly 16.8% of the total population. Therefore, rising geriatric populations are driving the gastric volvulus treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9382&type=smp

The gastric volvulus treatment market covered in this report is segmented –
1) By Type: Organo-Axial Volvulus, Mesentero-Axial Volvulus
2) By Treatment Type: Medication, Surgery
3) By Route of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Top Major Players:

• PAI Pharma
• Sun Pharmaceutical Industries Ltd.
• ANI Pharmaceuticals Inc.
• Fresenius SE and Co. KGaA
• Mayne Pharma Group Limited

North America was the largest region in the gastric volvulus market in 2023.

Product innovations are a key trend gaining popularity in the gastric volvulus treatment market. Major companies operating in the market are introducing innovative products to sustain their position in the gastric volvulus treatment market. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VELSIPITY (etrasimod). VELSIPITY (etrasimod) is a once-daily oral sphingosine-1-phosphate (S1P) receptor activator for people with moderate to severe active ulcerative colitis (UC). VELSIPITY’s official suggested dosage is 2 mg. ELSIPITY allows adults with moderately to severely active UC to achieve steroid-free resolution with an oral, once-daily pill that has a positive benefit-risk profile. The FDA’s approval of VELSIPITY today marks an important turning point for UC patients who require novel therapies for this long-term illness and are ready to begin advanced therapy.

The gastric volvulus treatment market report table of contents includes:
1. Executive Summary
2. Gastric Volvulus Treatment Market Characteristics
3. Global Gastric Volvulus Treatment Market Trends And Strategies
4. Gastric Volvulus Treatment Market – Macro Economic Scenario
5. Global Gastric Volvulus Treatment Market Size and Growth
…….
26. Global Gastric Volvulus Treatment Market Competitive Benchmarking
27. Global Gastric Volvulus Treatment Market Competitive Dashboard
28. Key Mergers and Acquisitions In Gastric Volvulus Treatment Market
29 Gastric Volvulus Treatment Market Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model